JP2021518400A5 - - Google Patents

Info

Publication number
JP2021518400A5
JP2021518400A5 JP2020550712A JP2020550712A JP2021518400A5 JP 2021518400 A5 JP2021518400 A5 JP 2021518400A5 JP 2020550712 A JP2020550712 A JP 2020550712A JP 2020550712 A JP2020550712 A JP 2020550712A JP 2021518400 A5 JP2021518400 A5 JP 2021518400A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
hydrogen
fluoro
Prior art date
Application number
JP2020550712A
Other languages
English (en)
Japanese (ja)
Other versions
JP7337086B2 (ja
JPWO2019180683A5 (https=
JP2021518400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/052364 external-priority patent/WO2019180683A1/en
Publication of JP2021518400A publication Critical patent/JP2021518400A/ja
Publication of JP2021518400A5 publication Critical patent/JP2021518400A5/ja
Publication of JPWO2019180683A5 publication Critical patent/JPWO2019180683A5/ja
Application granted granted Critical
Publication of JP7337086B2 publication Critical patent/JP7337086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550712A 2018-03-23 2019-03-22 スルファメート結合を有するstingモジュレーター化合物、及び製造及び使用の方法 Active JP7337086B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647227P 2018-03-23 2018-03-23
US62/647,227 2018-03-23
US201962821831P 2019-03-21 2019-03-21
US62/821,831 2019-03-21
PCT/IB2019/052364 WO2019180683A1 (en) 2018-03-23 2019-03-22 Sting modulator compounds with sulfamate linkages, and methods of making and using

Publications (4)

Publication Number Publication Date
JP2021518400A JP2021518400A (ja) 2021-08-02
JP2021518400A5 true JP2021518400A5 (https=) 2022-03-29
JPWO2019180683A5 JPWO2019180683A5 (https=) 2022-03-29
JP7337086B2 JP7337086B2 (ja) 2023-09-01

Family

ID=66397323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550712A Active JP7337086B2 (ja) 2018-03-23 2019-03-22 スルファメート結合を有するstingモジュレーター化合物、及び製造及び使用の方法

Country Status (4)

Country Link
US (2) US20210015915A1 (https=)
EP (2) EP3768685A1 (https=)
JP (1) JP7337086B2 (https=)
WO (1) WO2019180683A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Sting調節剤化合物、ならびに製造及び使用する方法
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
AU2021377229A1 (en) * 2020-11-11 2023-06-29 Biogen Ma Inc. Oligonucleotides, reagents and preparation thereof
PE20242344A1 (es) 2021-05-12 2024-12-16 Boehringer Ingelheim Int DERIVADOS DE PIRIDINA CON SUSTITUYENTES CICLICOS LIGADOS A N COMO INHIBIDORES DE cGAS
CN120344538A (zh) * 2022-11-09 2025-07-18 勃林格殷格翰国际有限公司 作为cGAS抑制剂的环状吡啶衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
US10092644B2 (en) 2013-11-22 2018-10-09 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
PE20170198A1 (es) * 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3546473B1 (en) * 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
CA3002236A1 (en) 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
RS67188B1 (sr) 2016-01-11 2025-10-31 Innate Tumor Immunity Inc Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG10201912074PA (en) * 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
WO2019118839A1 (en) * 2017-12-15 2019-06-20 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists

Similar Documents

Publication Publication Date Title
JP2021518400A5 (https=)
JP2016509047A5 (https=)
JP6716785B2 (ja) Hivウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP7515467B2 (ja) Vap-1の阻害剤
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2018536648A5 (https=)
Diana et al. [[(4, 5-Dihydro-2-oxazolyl) phenoxy] alkyl] isoxazoles. Inhibitors of picornavirus uncoating
JP2008545660A5 (https=)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2016510038A5 (https=)
CN111051297A (zh) Hiv衣壳抑制剂的胆碱盐形式
RU2019107938A (ru) Производное оксопиколинамида, способ его получения и его фармацевтическое применение
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
JP2019518046A5 (https=)
JPWO2020243415A5 (https=)
JP2008535903A5 (https=)
JP2016515561A5 (https=)
JP2015532295A5 (https=)
JP2020520955A5 (https=)
SA523442662B1 (ar) Apol1 مثبطات لـ وطرق استخدامها
JP2020536082A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2018534355A5 (https=)
JP2019520344A5 (https=)
JP2018502141A5 (https=)